Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Biomarker-Driven Study of Allogeneic Donor-Derived CAR-NK Cells With Antigen Selection by Tissue Biopsy and/or Liquid Biopsy Profiling in Participants With Relapsed/Refractory Advanced Solid Tumors (Single-Target vs Dual-Target Strategy)

NCT07410494 is registered in ClinicalTrials.gov with Essen Biotech as lead sponsor.

NCT NCT07410494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07410494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Biomarker-Driven Study of Allogeneic Donor-Derived CAR-NK Cells With Antigen Selection by Tissue Biopsy and/or Liquid Biopsy Profiling in Participants With Relapsed/Refractory Advanced Solid Tumors (Single-Target vs Dual-Target Strategy)
Lead sponsor
Essen Biotech
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 1, 2026
Completion date
December 28, 2028
Enrollment
85 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), breast cancer, cancer, colorectal cancer (locally advanced or metastatic), glioblastoma, liver cancer, melanoma (skin cancer), multiple myeloma (mm), lymphoma, large b-cell, diffuse (dlbcl), lymphoma, non hodgkin lymphoma, non-small cell lung cancer (nsclc), ovarian cancer, pancreatic ductal adenocarcinoma (pdac), prostate cancer - recurrent